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Background: Malaria control has been dramatically scaled up the past decade, mainly thanks to increasing
international donor financing since 2003. This study assessed progress up to 2010 towards global malaria impact
targets, in relation to Global Fund, other donor and domestic malaria programme financing over 2003 to 2009.
Methods: Assessments used domestic malaria financing reported by national programmes, and Global Fund/OECD
data on donor financing for 90 endemic low- and middle-income countries, WHO estimates of households owning
one or more insecticide-treated mosquito net (ITN) for countries in sub-Saharan Africa, and WHO-estimated malaria
case incidence and deaths in countries outside sub-Saharan Africa.
Results: Global Fund and other donor funding is concentrated in a subset of the highest endemic African
countries. Outside Africa, donor funding is concentrated in those countries with highest malaria mortality and case
incidence rates over the years 2000 to 2003. ITN coverage in 2010 in Africa, and declines in case and death rates
per person at risk over 2004 to 2010 outside Africa, were greatest in countries with highest donor funding per
person at risk, and smallest in countries with lowest donor malaria funding per person at risk. Outside Africa,
all-source malaria programme funding over 2003 to 2009 per case averted ($56-5,749) or per death averted
($58,000-3,900,000) over 2004 to 2010 tended to be lower (more favourable) in countries with higher donor malaria
funding per person at risk.
Conclusions: Increases in malaria programme funding are associated with accelerated progress towards malaria
control targets. Associations between programme funding per person at risk and ITN coverage increases and
declines in case and death rates suggest opportunities to maximize the impact of donor funding, by strategic
re-allocation to countries with highest continued need.
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With support from development partners, low- and
middle-income countries have intensified efforts to meet
intervention coverage and impact targets of the Millen-
nium Development Goals (MDGs) [1], the World Health
Assembly (WHA) and the Roll Back Malaria (RBM)
Partnership [2] (Table 1). International funding for ma-
laria control increased from US$149 million in 2000 to
approximately US$1.66 billion in 2011 [3,4]. The Global* Correspondence: ekorenromp@orange.fr
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distribution, and reproduction in any mediumFund has been a major contributor to this scale-up,
covering an estimated 40% of international assistance for
malaria from 2003 to 2008, and 63% of international
malaria funding in the year 2010 alone [3,5]. Between
2002 and 2011, Global Fund-supported malaria pro-
grammes delivered 230 million insecticide-treated nets
(ITNs) and 230 million malaria treatments across 84
low- and middle-income countries [5,6]. This external
funding is complemented by the United States President’s
Malaria Initiative (PMI), which, since 2005, has been a
significant donor for malaria control programmes in 19
countries in Africa and the Greater Mekong sub-region
in Asia.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Malaria targets in the Millennium Development
Goals and of the World Health Assembly and Roll Back
Malaria Partnership
MDG 6 − Combat HIV/AIDS, malaria and other diseases [1]:
• Target 6c: By 2015, have halted and begun to reverse the incidence
of malaria and other major diseases
• Indicator 6.6: Incidence and death rates associated with malaria
• Indicator 6.7: Proportion of children under-five sleeping under an
insecticide-treated bed net
MDG 4 − Reduce child mortality [1]:
• Target 4a: Reduce by two-thirds, between 1990 and 2015, the under-
five mortality rate.
World Health Assembly [43]:
• Reduce malaria cases by 75% from 2000 to 2015
• Reduce malaria-related deaths by 75% from 2000 to 2015.
Roll Back Malaria Partnership, June 2011 [2,3]:
• Objective 1: Near-zero malaria deaths by 2015.
• Objective 2: Reduce malaria cases by 75%, from 2000 to 2015.
• Objective 3: Eliminate malaria by 2015 in 10 new countries and in the
WHO European Region.
• Target 2.2 Sustain universal access to and utilization of prevention
measures: By 2015 and beyond, all countries sustain universal access
to and utilization of an appropriate package of preventive
interventions.
• Indicator: Proportion of households with at least one ITN.
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and artemisinin-based combination therapy (ACT), a
growing number of countries have reported decreasing
numbers of confirmed malaria cases and/or malaria-
attributed hospital admissions and deaths since 2000;
globally, malaria mortality has fallen by an estimated
25% [3,7].
RBM and WHO estimate the financing need for effect-
ive malaria control to exceed US$5 billion every year
through 2015; yet even at its 2011 peak, global funding
available for malaria remained far below this need, with
international disbursement totalling US$2 billion and
domestic financing a lower amount [3,8,9]. To allocate
available funding effectively and maximize the impact of
investments, it is critical to understand how and where
funding is advancing programme success in terms of
population coverage achieved as well as health im-
pact [3,9].
This study compares changes in the proportion of
households owning at least one ITN (for sub-Saharan
Africa countries) and in malaria cases and deaths (for
countries outside Africa) with levels of malaria
programme funding (from the Global Fund, other
donors and domestic governments) available to low- and
middle-income countries over the period 2003 to 2010.
Findings are discussed with a view towards informing
donor investment strategies and allocation policies.Methods
Malaria programme financing
Malaria programme funding in each endemic country
was expressed as the cumulative funding between 2003
(the first year of Global Fund malaria disbursements)
and December 2009, in current US dollars. To assess the
effects of funding on progress with malaria control,
given that available estimates on malaria cases and
deaths extended to 2010, analysis of funding data was
capped at December 2009, assuming a typical lag of one
year to in-country spending, programme implementation
[10] and ensuing impact on reducing malaria cases and
deaths.
Allocations from the Global Fund were taken as dis-
bursements through malaria grants [5,11]. Other-donor
gross disbursements included those from the USA Presi-
dent’s Malaria Initiative [12], World Bank [13], and other
bilateral and multilateral donors as reported through the
Organization for Economic Cooperation and Develop-
ment (OECD) Development Assistance Committee
(DAC)’s Creditor Reporting System [14]. Domestic fi-
nancing data was taken from reports by National Ma-
laria Control Programmes to WHO through the annual
World Malaria Report questionnaire [3]. Government
funding is expressed as programme expenditures, or as
budgets when a programme had not reported govern-
ment expenditures [15].
Total country funding was converted into funding per-
capita using national population sizes [16], and into
funding per person at risk using WHO estimates of na-
tional populations at risk [3]. For analyses, countries
were stratified into three groups, according to their level
of funding from all donors (Global Fund and other
donors combined) cumulated over 2003 to 2009 per per-
son at risk (Additional file 1). All-donor funding was
chosen as the criterion for country stratification, because
donor funding has increased relatively more than do-
mestic government funding over the period 2003 to
2009, and is more likely to be allocated to commodities
and other variable costs of malaria programmes, as
opposed to the more stable cost of human resources,
which is usually covered by national governments.
Insecticide-treated bed net coverage estimates
ITN coverage was assessed as the proportion of house-
holds that own one or more ITNs, estimated every year
by WHO and partners, for 41 malaria-endemic, low-
and middle-income countries in sub-Saharan Africa over
the years 2003 to 2010 [3]. The coverage estimation is
based on data from nationally representative household
surveys (Demographic and Health Surveys, Multiple In-
dicator Cluster Surveys and Malaria Indicator Surveys),
manufacturer reports of ITN procurement and National
Malaria Programme reports of ITN distribution [17].
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risk of malaria transmission, assuming that in countries
with <100% of the national population living at malaria
risk, all available ITNs are owned by households in ma-
larious areas [17]. ITN coverage estimates for national
population at risk were not available for countries out-
side sub-Saharan Africa, where malaria transmission is
often focused in certain regions, so that national surveys
do not give a meaningful indication of the level of pro-
tection in populations actually living in areas with ma-
laria transmission.
Malaria case and death estimates
Assessments focus on 49 malaria-endemic, low- and
middle-income countries outside sub-Saharan Africa,
after exclusion of Turkey, Paraguay and Kyrgyzstan, with
income levels taken from the World Bank income classi-
fication of 2005 [18]. All of these 49 countries were eli-
gible for Global Fund malaria support up to 2010.
Turkey, Paraguay and Kyrgyzstan were excluded because
they had very few cases throughout the 2000s and small
populations at risk, resulting in extremely high levels of
funding per person at risk that would have distorted
analyses.
WHO’s case estimates for these countries were based
on numbers of reported, parasitologically confirmed
malaria cases from national health information systems
(HIS), adjusted for reporting completeness, the propor-
tion of suspected malaria cases that are parasite-positive,
the proportion of confirmed cases due to each Plasmo-
dium species, and the extent to which patients use pub-
lic sector health facilities [3,15,19,20]. Death estimates
were derived by multiplying the number of Plasmodium
falciparum malaria cases estimated for each country by
a fixed case fatality rate [3,20]. Case and death estimates
were evaluated over the period 2004 to 2010.
For most countries in sub-Saharan Africa, the overall
quality of surveillance data did not allow a convincing
estimate of total cases to be made from reported cases
[3]. For these countries, numbers of cases and deaths are
estimated using an epidemiological model in which the
trend in each country over time is a function of that
country’s increase in household ITN coverage [3]. The
dependence of these case and death trend estimates on
national ITN coverage trends, itself already considered
as progress outcome earlier in the current analysis, pre-
cluded an independent assessment of case and death
trends in relation to programme funding for the sub-
Saharan African countries.
Malaria funding per case or death averted
Malaria funding allocated (cumulated over 2003–2009)
was computed per case or death averted over 2004–
2010 for each of the 49 countries outside sub-SaharanAfrica. Each country’s time trend in case or death rates
over 2004–2010 was estimated in a linear regression,
and the predicted value for each of these years compared
with case and death rates over 2000–2003 as the base-
line, while adjusting for annual population growth. The
four-year period 2000 to 2003 (rather than 2003 or 2004
alone) served as the baseline period, because in low-
endemic countries outside Africa, ongoing malaria fund-
ing serves not only to reduce case and death burden to
below 2004 levels, but in the first place to prevent a re-
surgence to even much higher case and death rates (as
seen in 2000 and in the decades before) that would likely
reappear if the control stopped.
Country-level programme funding per case or death
averted were then summarized for three country groups
(tertiles) as the median and interquartile range across
the 16 or 17 countries in each group.
Results
Malaria financing
Total malaria programme funding in the 90 countries
increased from US$317 million in 2003 to US$2.2 billion
in 2009. The Global Fund, other donors and domestic
governments accounted for 47%, 32% and 21%, respect-
ively in 2009 (Figure 1a and b). From 2003 to 2009, Glo-
bal Fund malaria funding increased 21-fold, other-donor
malaria funding increased 14-fold, and domestic govern-
ment funding increased two-fold. Among non-Global
Fund donors, in 2009 the USA Presidential Malaria Ini-
tiative contributed around 60% of malaria disbursements
in 2009, the World Bank 7%, and the United Kingdom
direct bilateral funding through the Department for
International Development 6%.
Over 2003 to 2009, funding from all sources combined
increased from US$110 million to US$1.55 billion in
sub-Saharan Africa (Figure 1a), and from US$207 mil-
lion to US$620 million outside Africa (Figure 1b).
Within sub-Saharan Africa, malaria funding from the
Global Fund and other donors was concentrated in a
common subset of countries, with half of total Global
Fund funding going to only nine countries, and half of
other-donor funding going to the same nine countries
(Figure 1c). These nine countries were all in east and
west Africa (Additional file 1), with stable high rates of
malaria case incidence and mortality.
Domestic government funding, in contrast, was con-
centrated in countries of lower endemicity, with lower
case and death rates, in the Americas, Caribbean and
Southeast Asia (Figure 1b & d and Additional file 1).
Among non-Africa countries, domestic funding
increased from $174 million in 2003 to US$ 332 million
in 2009 (Figure 1b). Within Africa, domestic funding
increased more steeply, from US$ 48 million in 2003 to
$125 million in 2009 (Figure 1a).
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Figure 1 Malaria programme funding from Global Fund, other donors and domestic governments: aggregated across endemic low-
and middle-income countries, by calendar year: (a) 41 countries in sub-Saharan Africa; (b) 49 countries outside sub-Saharan Africa; and
by individual country cumulated over 2003 to 2009, with countries sorted by total amount of Global Fund funding over 2003 to 2009:
(c) in sub-Saharan Africa; (d) outside sub-Saharan Africa. Note to Figure 1: Countries with a >0 $ funding level vary among the years; over
2003–2009 summed, out of 90 countries, 16 countries had no Global Fund funding; 14 had no other-donor funding, and eight no domestic
funding. From government malaria programme budgets reported to WHO by end-2011 [3], those of Burundi in 2003–2006 and Tanzania in 2008–
9 were excluded as they were grossly inconsistent with budgets reported by those countries in neighbouring years.
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ITN coverage in sub-Saharan Africa increased from 4%
in 2003 to 63% in 2010 in the 14 countries with largest
donor malaria funding per person at risk over 2003 to
2009, from 3% to 46% in the 14 countries with medium
donor funding per person at risk, and from 2% to 36% in
the 13 countries with lowest donor malaria funding per
person at risk (Figure 2).
Malaria case and death declines, by level of donor
funding
Among 49 countries outside sub-Saharan Africa, the 17
with highest donor malaria funding per person at risk
had the highest rates of malaria cases and deaths over
2000–2003, and the largest subsequent declines in theserates, both proportionally and as rate differences com-
pared to the 2000–2003 rates (Figure 3, red lines).
Among these 17 countries, overall time trends were
driven by the countries with largest numbers of cases
and deaths: Papua New Guinea, Cambodia, Sri Lanka,
Laos and Timor Leste.
Among the 16 countries with an intermediate level of
donor malaria funding per person at risk, an overall
slight decline in case and death rates was driven by the
relatively high-burden countries: Indonesia, Myanmar
and Yemen, where case and death rates were stable; and
Afghanistan and Bangladesh, where case and death rates
declined (Figure 3, blue lines).
Among the 16 countries with lowest total donor ma-
laria support per person at risk (Figure 3, green lines),
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Figure 2 Progress toward target of universal coverage with ITNs (operationalized as 100% of households owning ≥one ITN [3]) among
41 malaria-endemic low- and middle-income countries in sub-Saharan Africa, up to 2010, according to the level of countries’ malaria
programme funding from donors per person at risk over 2003 to 2009.
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dominated by India, which experienced a very slight de-
cline. Among these countries, Pakistan showed a stable
or fluctuating trend, whereas case and death rates
declined in most Latin American countries including
Brazil.
Malaria funding per case or death averted
Among countries outside sub-Saharan Africa, programme
funding from all sources summed over 2003–2009 per
case prevented over 2004–2010 was US$78 (interquartile
range US$45−146) in the 17 countries with highest donor
funding per person at risk, US$56 (31−260) in the 160
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Figure 3 Progress in reducing (a) malaria case incidence rate, and (b)
programme funding from all donors combined, over 2003 to 2009 [3
outside sub-Saharan Africa.countries with intermediate levels of donor funding
per person at risk, and US$5,749 (506−30,227) in the 16
countries with lowest donor malaria support per person at
risk (Table 2).
Per death prevented over 2004–2010, 2003–2009
funding averaged US$57,654 (24,997−5,484,870) in the
17 countries with highest donor funding per person at
risk, US$92,286 (23,391−1,560,418) in the next 16 coun-
tries, and US$3,903,107 (368,839− 19,627,442) in the 16
countries with lowest donor malaria support per person
at risk. The highest costs per death averted were esti-
mated for countries with very few malaria deaths (Azer-
baijan and Honduras in the highest-funding group;0.00
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Table 2 Estimated cases and deaths prevented over 2004–2010 (relative to 2000–2003 baseline) per dollar total
malaria programme funding over 2003–2009, 49 countries outside sub-Saharan Africa
Countries, outside sub-Saharan Africa 17 with highest donor funding
per person at risk
16 with medium donor
funding per person at risk
16 with lowest donor funding
per person at risk
Cases prevented over 2004–2010, relative
to 2000–3 rates (millions)
6.2 18 20
Deaths prevented over 2004–2010, relative
to 2000–3 rates (thousands)
11 15 51
Malaria funding, millions
US$ 2003-2009
Global Fund $ 214 $ 272 $ 115
Other donors $ 26 $ 51 $ 85
Governments
domestic
$ 178 $ 243 $ 1,443
All sources
combined
$ 416 $ 567 $ 1,643
2003-2009 all-source funding per case
prevented, as median across countries
$ 78 (45−146) $ 56 (31−260) $ 5,749 (506−30,227)
2003-2009 all-source funding per death
prevented, as median across countries
$ 57,654 (24,997−5,484,870) $ 92,286 (23,391−1,560,418) $ 3,903,107 (368,839−
19,627,442)
Note: Numbers in brackets are interquartile range across the countries in each group.
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and Iraq in the medium-funding group; and Mexico and
El Salvador in the lowest-funding group), or with an in-
crease in malaria deaths (Timor-Leste and Venezuela in
the highest-funding group; Indonesia in the medium-
funding group, and Dominican Republic and Costa Rica
in the lowest-funding group). The presented upper limits
of the interquartile ranges (indicating the cost level that
75% of countries in a funding-level group are below),
however illustrate the wide ranges in cost per death
averted among all countries.
Discussion
The synthesis of malaria programme funding and control
progress data from countries worldwide confirms that
global malaria donor funding is generally well targeted to
the countries with highest malaria transmission and case
and death rates. Higher donor funding per person at risk
was also associated with greater increases in household
ITN ownership among African countries, confirming
similar observations made earlier [10,15,17,21]. Outside
Africa, increased donor funding was associated with larger
proportional malaria case and death rate declines.
Outside Africa, all-source programme funding per case
averted or death averted tended to be lower in the coun-
tries with higher donor malaria support per person at
risk (Table 2). These gradients illustrate an overall effect-
ive targeting of global donor allocations to countries
with highest return on malaria investments. Neverthe-
less, there was large variation among countries within
each group in programme funding per case or death
averted, with overlapping ranges across the three tertiles
of countries. Apparently, donor allocations partially coun-
terbalance the enormous differences among countries inlevels of domestic funding per person at risk and per case
or death averted (Figure 1c and d), but they do not com-
pletely turn around the cross-country imbalances so as to
maximize the possible health impact for available global
funding.
The presented ‘costs’ per case or death averted should
not be considered as cost-effectiveness ratios, which are
typically lower (more favourable) [22,23], for three rea-
sons. First, case/death levels averaged over year
2000−2003 served as the baseline against which cases
and deaths averted were calculated; however, in reality,
case and death rates in the non-African countries eva-
luated might well resurge to above 2000−2003 levels if
malaria programme funding and control stopped
altogether. Second, the time horizon for cases and
deaths averted was limited to 2010, without including
additional impact achieved over 2011–2012 from the –
comparatively large – programme spending in 2009–
2010. Third, total funding on all malaria services
included case management and programme administra-
tion, rather than just the cost of any single intervention.
Although donor malaria funding is generally well tar-
geted to the highest-need countries with lowest ITN
coverage and highest case and death rates at baseline,
there remain exceptions. As noted before [10,24-26],
donor funding per person at risk was very high in some
small countries of relatively low malaria burden and high
income, including Bhutan, Comoros, Laos, Suriname,
and in Africa Sao Tome and Principe and Equatorial
Guinea (both excluded from analyses), Gabon, Namibia
and Swaziland. In contrast, Burkina Faso, the Demo-
cratic Republic of Congo, Mali, Cote d’Ivoire and Nigeria
had surprisingly low donor malaria funding relative to
their populations at risk.
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beyond the scope of the current study, and would have
to consider not only actual programme allocations but
also countries’ domestic funding capacity. In addition,
economies of scale will tend to lower costs per person
reached in large-scale, nation-wide programmes in the
highest-endemic countries, compared to settings with
only focal malaria that require more expensive pre-
elimination and elimination strategies [27]. Also, effect-
ive progress in control does not necessarily mean that
impact would be sustained after lowering the inputs – as
experiences with malaria resurgence in Sri Lanka, Mada-
gascar and other countries have shown. According to
WHO estimates, overall global funding for malaria con-
trol falls short of the global need [3,8,9], and increasing
overall malaria funding is equally important as optimiz-
ing funding allocations. Nevertheless, the large variation
in funding per person at risk (Additional file 1) and the
only moderately strong association between funding per
case or death averted and level of national donor fund-
ing per person at risk (Table 2) suggest a scope for fur-
ther enhancing value for money in international malaria
financing, through more strategic allocation of available
funding toward the highest-endemic countries with the
highest continued need.
In 2011, the Global Fund revised its eligibility,
prioritization and counterpart financing policy. From
2012 onwards all supported countries are required to
make a minimum domestic government co-funding con-
tribution, of a proportion increasing with country in-
come and with the years of each grant [28,29]. The
increased counterpart financing requirement on upper-
middle income countries should result in a gradual shift
of portfolio allocations toward lower-income countries.
This policy change therefore has the potential to facili-
tate better targeting of Global Fund funding to benefit
countries with the highest continuing need, an approach
also emphasized in the Global Fund’s 2012–2016 Stra-
tegy ‘Investing for impact’ [30].
Limitations
Uncertainties and potential inaccuracies in country ITN
coverage and case and death trend estimates [20,21,31]
limited the power to assess associations between funding
and health impact. The methods for producing estimates
of cases and deaths outside of Africa adjust the number
of reported cases to take into account the proportion of
cases that are not captured by a surveillance system.
While helping to make numbers more comparable be-
tween countries, and filling gaps where data are missing,
the estimates rely on relationships between variables that
are uncertain, and draw upon data that may have been
imprecisely measured, or measured in previous years
and projected forward. Thus estimates of the number ofmalaria cases or deaths are accompanied by a large de-
gree of uncertainty, and inferences concerning trends
are less certain than those made directly from good
quality surveillance data. In particular, the number of
malaria deaths is estimated by using a fixed case fatality
rate which does not take into account varying access to
treatment. For sub-Saharan Africa, lack of data on ma-
laria cases and deaths narrowed the analysis to house-
hold ownership of ITNs. Although a reasonable
predictor of ITN usage [32,33] and associated reductions
in under-five mortality, malaria parasitaemia and anae-
mia [34-36], ownership of one or more ITNs is not a
precise indicator of the extent to which universal protec-
tion for all household members is achieved.
A further limitation is incompleteness and varying
quality of data on domestic government financing. Of
the 90 malaria-endemic countries analysed, eight did not
report domestic malaria funding to WHO for any of the
years 2003 to 2009, and 25 countries did not report do-
mestic funding in 2009. Under-reporting is plausible
notably for domestic spending on malaria case manage-
ment, which is typically not allocated specifically to the
malaria programme but rather absorbed within districts’
overall health budgets. While donor funding is some-
times allocated predominantly to commodity needs of
malaria programmes [10,15,21], domestic contributions
may more often concern the infrastructure, staff and
programme management [3]. A recent assessment of
global malaria funding over 2006 to 2010 found similar
annual funding levels as this study for the Global Fund
and other donors, but slightly higher domestic funding –
the latter based on government budgets reported by
grant recipients to the Global Fund, as opposed to the
programme expenditures reported to WHO used
here [26].
Because of these imperfections in both national fund-
ing and health outcome data, this study assessed their
relationship only across groups of countries, and not at
the level of individual countries. Importantly, whether in
country groups or at the level of individual countries,
‘ecological’ correlations as found in the current observa-
tional analysis will not necessarily indicate a true causal
impact of programme funding. Among several alterna-
tive explanations, programme funding may be associated
with increased progress if donors’ funding allocation cri-
teria would effectively prioritize those countries with
best programme implementation capacity. Notably the
Global Fund selects proposals for grants based on tech-
nical soundness and demonstrated effectiveness, fol-
lowed by performance-based grant renewal [5]. The
current low per-person-at-risk donor in some countries
in part reflects the challenges that these countries face
with effective implementation owing to security con-
cerns, civil strife, limited technical, managerial and
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such countries may not necessarily yield equally high
returns on investment as observed in other countries.
Finally, the study did not consider allocative and tech-
nical efficiency in malaria programmes as determinants
of progress in control. In reality, not only the funding
amount, but also the appropriateness of its allocation
across prevention, diagnosis and treatment services,
and the − varying − efficiency in delivering these services
[37] will influence the relations between funding and
health outcome.
To refine these analyses will require improving
country-level case and death trend estimates, based on
the WHO’s new guidelines for scaling-up malaria diag-
nosis [38] and for malaria surveillance [39,40], and the
ongoing roll-out of parasitological diagnosis notably in
African countries [41]. On the financing tracking side,
new standards are needed for reporting of national ma-
laria programme financing, to improve quality, transpa-
rency, and completeness [42].
Conclusion
In conclusion, malaria programme financing from the
Global Fund and other sources is associated with
increased ITN coverage scale-up, a key determinant of
malaria burden declines in Africa, and with larger pro-
portional case and death rate declines among countries
outside Africa. Achieving MDG6, WHA [43] and RBM
targets globally will require accelerated case and death
declines, through intensified scale-up of ITN distribution
and other key prevention and treatment services.
Outside Africa, programme funding per case or death
prevented outside Africa tended to be lower in the coun-
tries that received higher donor funding per person
at risk. The associations shown between funding and
impact and the large variations in funding per person at
risk suggest opportunities to advance malaria control
and maximize the impact by increasing programme
funding and strategically allocating available donor funds
to countries with the highest continued need.
Additional file
Additional file 1: Country data: all-donor and domestic funding
national totals and funding per person at risk, estimated malaria
cases and deaths rates in 2008 for countries outside sub-Saharan
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